Literature DB >> 17008123

Herd protection against influenza.

W Paul Glezen1.   

Abstract

Mortality and hospitalization rates due to influenza have risen despite increasing vaccine coverage for the most vulnerable population; however, those most vulnerable to complications and death are the least likely to respond to the vaccine. New strategies for influenza control are needed and indirect effectiveness (herd protection) has been demonstrated for several currently used vaccines - rubella, H. influenzae type b, pneumococcus varicella and hepatitis A. The Japanese schoolchildren program provided proof of concept of indirect effectiveness of influenza vaccine. The Central Texas field trial has demonstrated significant herd protection of adults utilizing the live, attenuated influenza vaccine (LAIV) to children. Immunization of <20% of children at the intervention site resulted in an 8-18% reduction of medically attended acute respiratory illness in adults compared to rates in the comparison sites. LAIV given by nasal spray is efficacious against matched and poorly matched prevalent strains, easy to administer and readily accepted by children for annual immunization. School-based clinics could provide a platform for rapid deployment of vaccine accessible to all segments of the population. This strategy could be critical for control of pandemic influenza.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008123     DOI: 10.1016/j.jcv.2006.08.020

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  36 in total

1.  Childhood Hib vaccination and pneumonia and influenza burden in US seniors.

Authors:  Steven A Cohen; Saifuddin Ahmed; Ann C Klassen; Emily M Agree; Thomas A Louis; Elena N Naumova
Journal:  Vaccine       Date:  2010-05-08       Impact factor: 3.641

2.  Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006.

Authors:  Steven A Cohen; Kenneth K H Chui; Elena N Naumova
Journal:  J Am Geriatr Soc       Date:  2011-01-28       Impact factor: 5.562

Review 3.  Economic evaluations of childhood influenza vaccination: a critical review.

Authors:  Anthony T Newall; Mark Jit; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2012-08-01       Impact factor: 4.981

4.  Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign.

Authors:  Carlos G Grijalva; Yuwei Zhu; Lone Simonsen; Marie R Griffin
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

5.  Modelling mitigation strategies for pandemic (H1N1) 2009.

Authors:  Marija Zivkovic Gojovic; Beate Sander; David Fisman; Murray D Krahn; Chris T Bauch
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

6.  Strategies for improving influenza immunization rates among hard-to-reach populations.

Authors:  David Vlahov; Micaela H Coady; Danielle C Ompad; Sandro Galea
Journal:  J Urban Health       Date:  2007-07       Impact factor: 3.671

7.  Influenza vaccination rates of children in households with high-risk adults.

Authors:  Ru-Chien Chi; Gayle E Reiber; Benjamin A Lipsky; Edward J Boyko; Kathleen M Neuzil
Journal:  Public Health Rep       Date:  2010 Mar-Apr       Impact factor: 2.792

8.  Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan.

Authors:  Kiyoko Iwatsuki-Horimoto; Taisuke Horimoto; Daisuke Tamura; Maki Kiso; Eiryo Kawakami; Shuji Hatakeyama; Yasuhiro Ebihara; Tomohiko Koibuchi; Takeshi Fujii; Kazuo Takahashi; Masayuki Shimojima; Yuko Sakai-Tagawa; Mutsumi Ito; Saori Sakabe; Ayaka Iwasa; Kei Takahashi; Takashi Ishii; Takeo Gorai; Koichiro Tsuji; Aikichi Iwamoto; Yoshihiro Kawaoka
Journal:  Clin Vaccine Immunol       Date:  2011-02-23

9.  Annual influenza vaccination.

Authors:  David A Kelly; David J Macey; Donna B Mak
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  The 2009 H1N1 pandemic influenza virus: what next?

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  MBio       Date:  2010-09-28       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.